Synthesis of antidiabetic rosiglitazone derivatives

Details Synthesis of antidiabetic rosiglitazone derivatives Synthesis of antidiabetic rosiglitazone derivatives

Filed on

2005-05-03

Date issued

2009-10-06

Examiner

Morris, Patricia L (Department: 1625)

Patent Class

Organic compounds -- part of the class 532-570 series

SubClass

Organic compounds

SubSubClass

Heterocyclic carbon compounds containing a hetero ring...

Type

Reexamination Certificate

Status

active

Patent number

07598387

Description

ABSTRACT:
A process of preparing rosiglitazone, or a pharmaceutically acceptable salt thereof, which process employs an intermediate metabisulphite complex of 4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzaldehyde, which metabisulphite complex is represented by following formula (III):where X represents an alkali metal. The present invention further provides rosiglitazone, or a pharmaceutically acceptable salt thereof, prepared by the above process.

REFERENCES:
patent: 0 306 228 (1989-03-01), None
patent: 2 007 537 (1989-06-01), None
patent: WO 99/57123 (1999-11-01), None
patent: WO 02/051823 (2002-07-01), None
Mueller, Eugen, “Hydrogen sulphite compounds of saturated aldehydes,” Houben-Weyl Methoden der Organischen Chemie, vol. 2, No. 1, 1954, George Thieme Verlag, Stuttgart, De, pp. 482-488, XP-002320925.
Foreign communication from a related counterpart application—International Search Report, PCT/GB2005/001671, Aug. 16, 2005, 5 pages.
Foreign communication from a related counterpart application—International Preliminary Report on Patentability, PCT/GB2005/001671, Apr. 3, 2006, 6 pages.

Affiliated with

Also associated with

Rating

Synthesis of antidiabetic rosiglitazone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthesis of antidiabetic rosiglitazone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of antidiabetic rosiglitazone derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4053260